Piper cubeba extract

Piper cubeba extract containing 16.53% CUBEBIN that targets multiple aspects of the androgen-signalling pathway; a potential phytotherapy against prostate cancer growth

Also Known As:

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Drewe, Juergen: 2 articles (02/2008 - 01/2008)
2.	Kreuter, Matthias: 2 articles (02/2008 - 01/2008)
3.	Yam, Jianying: 2 articles (02/2008 - 01/2008)
4.	Cardin, Laila Toniol: 1 article (01/2022)
5.	Cunha, Nayanne Larissa: 1 article (01/2022)
6.	E Silva, Marcio Luis Andrade: 1 article (01/2022)
7.	Gusson-Zanetoni, Juliana Prado: 1 article (01/2022)
8.	Henrique, Tiago: 1 article (01/2022)
9.	Laurentiz, Rosangela Silva: 1 article (01/2022)
10.	Oliani, Sonia Maria: 1 article (01/2022)

Related Diseases

1.	Leukoencephalopathies 01/01/2014 - "Significantly more P9605 patients developed leukoencephalopathy compared with P9201 patients (68%, 95% confidence interval 49%-83% vs. 22%, 95% confidence interval 5%-44%; P=0.001) identified as late as 7.7 years after the end of treatment. " 01/01/2014 - "In this study, neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201). "
2.	Breast Neoplasms (Breast Cancer) 04/10/2015 - "Cytotoxic activity of Piper cubeba extract in breast cancer cell lines." 02/01/2008 - "We found that P9605 significantly inhibited growth induced by beta-estradiol in MCF-7, a human breast cancer cell line. "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/2014 - "A total of 66 children from 16 Pediatric Oncology Group institutions with "standard-risk" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605. " 01/01/2014 - "Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence? "
4.	Wounds and Injuries (Trauma) 01/01/2015 - "Evaluation of the effectiveness of Piper cubeba extract in the amelioration of CCl4-induced liver injuries and oxidative damage in the rodent model."
5.	Viremia 01/01/2012 - "Prolonged passage of the KFDV strain P9605 in monkey kidney tissue culture resulted in a markedly reduced virulence of the virus for both species; peak viremia titers in monkeys decreased by 2.5 to 4.0 log LD 50 (p= 0.001), and the mortality decreased to 10% (p= 0.001). " 01/01/2012 - "Experimental infection of the langur and the bonnet macaque with early mouse passage KFDV strain P9605 resulted in a viremia of up to 11 days duration, peak viremia titers as high as 10 (9), and death in 82 = 100% of the animals. "

Related Drugs and Biologics

1.	Cyclooxygenase 2 (Cyclooxygenase-2)
2.	Lignans
3.	Proteins (Proteins, Gene)
4.	Methotrexate (Mexate)
5.	Estradiol (Delestrogen)
6.	DNA (Deoxyribonucleic Acid)
7.	Androgens

Related Therapies and Procedures

1.	Therapeutics
2.	Phytotherapy (Herbal Therapy)